Context Therapeutics, Inc. (CNTX)
Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, which include, but are not limited to, breast, ovarian and endometrial cancer.
Our first program and lead product candidate, onapristone extended release (“ONA-XR”), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependent cancers.
We believe that ONA-XR, in combination with current standard-of-care anti-estrogens, has the potential to significantly improve clinical outcomes. ONA-XR is currently being evaluated in three Phase 2 trials, one Phase 1b/2 trial and two Phase 0 biomarker pharmacodynamic trials in women with primary or metastatic breast, ovarian and endometrial cancers.
These trials are intended to establish safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity at the recommended Phase 2 dose of ONA-XR to guide potential advancement in Phase 3 development in 2023.
|IPO Date||Oct 20, 2021|
3675 Market Street, Suite 200
Philadelphia, PA 19104
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Martin Lehr||Co-Founder, Chief Executive Officer and Director|
|Dr. Tarek Sahmoud||Chief Medical Officer|
|Dr. Bill Rencher Ph.D.||Head of CMC and Regulatory|
|Dr. Felix Kim Ph.D.||Co-founder and Chair of Scientific Advisory Board|
|Eileen Kittrick CPA||Controller|
|Alex Levit Esq.||Chief Legal Officer and Corporate Secretary|
|Dr. Evan G. Dick||Senior Vice President of Research & Development|